183 related articles for article (PubMed ID: 38564315)
1. Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression.
Chen Z; Zeng L; Chen Z; Xu J; Zhang X; Ying H; Zeng Y; Yu F
Technol Cancer Res Treat; 2024; 23():15330338241241935. PubMed ID: 38564315
[TBL] [Abstract][Full Text] [Related]
2. Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma.
Huang S; Zhang C; Sun C; Hou Y; Zhang Y; Tam NL; Wang Z; Yu J; Huang B; Zhuang H; Zhou Z; Ma Z; Sun Z; He X; Zhou Q; Hou B; Wu L
Aging (Albany NY); 2020 Feb; 12(3):3025-3041. PubMed ID: 32045367
[TBL] [Abstract][Full Text] [Related]
3. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
4. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
5. Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes.
Yan J; Cao J; Chen Z
BMC Cancer; 2021 Feb; 21(1):175. PubMed ID: 33602168
[TBL] [Abstract][Full Text] [Related]
6. CLEC3B as a Potential Prognostic Biomarker in Hepatocellular Carcinoma.
Xie XW; Jiang SS; Li X
Front Mol Biosci; 2020; 7():614034. PubMed ID: 33553242
[TBL] [Abstract][Full Text] [Related]
7. An M0 macrophage-related prognostic model for hepatocellular carcinoma.
Zhang Y; Zou J; Chen R
BMC Cancer; 2022 Jul; 22(1):791. PubMed ID: 35854246
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of exosomal CLEC3B in hepatocellular carcinoma promotes metastasis and angiogenesis via AMPK and VEGF signals.
Dai W; Wang Y; Yang T; Wang J; Wu W; Gu J
Cell Commun Signal; 2019 Sep; 17(1):113. PubMed ID: 31477130
[TBL] [Abstract][Full Text] [Related]
9. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
10. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
11. Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma.
Chen Y; Yang S; Hu J; Yu C; He M; Cai Z
PLoS One; 2016; 11(5):e0154939. PubMed ID: 27183310
[TBL] [Abstract][Full Text] [Related]
12. Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.
Zahid KR; Han S; Zhou F; Raza U
Cell Oncol (Dordr); 2019 Feb; 42(1):55-66. PubMed ID: 30238408
[TBL] [Abstract][Full Text] [Related]
13. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
15. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.
Lu Y; Wang S; Chi T; Zhao Y; Guo H; Wang H; Feng L
Sci Rep; 2023 Nov; 13(1):18978. PubMed ID: 37923899
[TBL] [Abstract][Full Text] [Related]
16. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
18. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines.
Wang XK; Liao XW; Yang CK; Liu ZQ; Han QF; Zhou X; Zhang LB; Deng T; Gong YZ; Huang JL; Huang R; Han CY; Yu TD; Su H; Ye XP; Peng T; Zhu GZ
J Cell Physiol; 2020 Oct; 235(10):7003-7017. PubMed ID: 32037547
[TBL] [Abstract][Full Text] [Related]
19. Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis.
Zhen Z; Shen Z; Hu Y; Sun P
Aging (Albany NY); 2021 Jul; 13(13):17707-17733. PubMed ID: 34252885
[TBL] [Abstract][Full Text] [Related]
20. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
